🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Raj Chakraborty Muhammad Husnain,MD Leukemia Journal Yes. I hope so. The approach of indefinite treatment till progression as the experimental arm can result in a negative trial by compromising safety / OS — and we may lose out on a good treatment that works quite well with a reduced frequency/ time limited schedule.

9/ #EHA2025 #MMsm CAR-T: Not #ASCO25 per se but of course must add: S201 iMMagine-1 (Gurbakhash Kaur): Per press release, now n=117 anito-cel recipients (3+ prior LOT). MRD neg 70/117, 12-mo PFS 79%. 🙅🏼‍♂️ MNTs, 🙅🏼‍♂️ parkinsonism, 🙅🏼‍♂️ IEC enterocolitis. I hope this gets approved ASAP!

Congressman Greg Murphy, M.D. Rather than weaponizing the concept of calling to promote acceptance of an untenable system, perhaps someone who left medicine to enter politics could now exercise their power to reduce the administrative burden on those of us who still practice? I only want to care for patients

Robert Z. Orlowski The rest is history. The phase I trial led by Robert Z. Orlowski included a few myeloma patients. Remarkable activity including a complete response was observed in refractory myeloma. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Robert Z. Orlowski Journal of Clinical Oncology Simultaneously preclinical studies showing the activity of PS-341 in myeloma were done Dana-Farber by Ken Anderson and colleagues. PS-341 was felt to be highly active against myeloma. Bedside and bench worked side by side. aacrjournals.org/cancerres/arti…

1/3: Many thanks for keeping this attribution alive. The original paper in J Neurochem by Wilk & Orlowski on what was first called the multicatalytic proteinase complex (before it was rebranded by others as the proteasome) was published in 1980.

2/3: It was published in J Neurochem because the dogma at the time was that proteases were small proteins. Major journals to which Wilk & Orlowski submitted their work (ie. Science) would not accept that there was such a large particle that had proteolytic capacity & rejected it.

3/3: This later was rebranded as the 20S proteasome. Beyond Wilk & Orlowski, others who deserve credit for proteasome research include Martin C. Rechsteiner (for finding the 26S proteasome) and Alfred L. Goldberg (for finding the ATP dependence of proteolysis).

The future of myeloma care will regularly include the word cure! open.substack.com/pub/rafaelfons…

The International Myeloma Working Group (IMWG) was formed in 2002 by International Myeloma Foundation bringing together myeloma experts committed to working together from around the world. IMWG.org Few diseases have a united collaborative group like this. The first papers were:

We work collaboratively with the Myeloma Society IMWG standing subcommittees work on major areas such as MGUS/SMM, bone disease, immunotherapy, patient reported outcomes, MRD/Mass Spec. myeloma.org/international-…

Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia. @mayomyeloma Leukemia nature.com/articles/s4137…

Thanks as always Mike for putting these together!! Top myeloma #MMsm abstracts to look for at #ASCO25👇🏼

New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance iStopMM JAMA Oncology #mmsm jamanetwork.com/journals/jamao… Important data coming to support need for new ranges of normal free light chains based on eGFR👇

#Myeloma Paper of the Day: New light chain #MGUS definition -> 1.54% prevalence (1.46-1.63) using standard & 0.27% (0.23-0.30) w/ revised intervals; 0/1006 persons meeting LC-MGUS criteria w/ standard but not based on revised intervals progressed: pubmed.ncbi.nlm.nih.gov/40440024/. #mmsm

Myeloma and its precursor, monoclonal gammopathy, are more common in individuals with Black ancestry and are associated with immune dysfunction. ow.ly/x4X750W0wxv #immunobiologyandimmunotherapy #plasmacelldisorders

MD Anderson researchers shared over 35 posters at the #ASCO25 Sunday morning poster session. This includes results from the QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in patients with relapsed or refractory multiple myeloma, presented by Krina Patel. ASCO

#ASCO25 Tuesday myeloma session. As nicely summarized by Suzanne Lentzsch, MD, PhD studies presented this morning re-emphasize that anti-CD38 quads should be the new SoC in NDMM, whether transplant eligible or not. Quads led to higher sustained MRD negativity rates & outcome even in HR #mmsm

Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in #MultipleMyeloma at #ASCO25 globenewswire.com/news-release/2… “The durability and consistency we're seeing with CARVYKTI in the CARTITUDE-1 study is truly remarkable,” said Sundar Jagannath, MD Icahn School of Medicine at Mount Sinai